Human Reproduction Update, Vol.8, No.1 pp. 1±9, 2002
Alternative approaches in IVF*
Bart C.J.M.Fauser1,7, Philippe Bouchard2, Herjan J.T.Coelingh Bennink3, John A.Collins4,
Paul Devroey5, Johannes L.H.Evers6 and Andre van Steirteghem5
1
Division of Reproductive Medicine, Erasmus University Medical Center Rotterdam, The Netherlands, 2Service d'Endocrinology,
HoÃpital St Antoine, Paris, France, 3NV Organon, Research and Development Unit, Oss, The Netherlands, 4McMaster, Hamilton,
Canada, 5Center of Reproductive Medicine, Free University, Brussels, Belgium and 6Department of Obstetrics and Gynaecology,
University of Maastricht, The Netherlands
7
To whom correspondence should be addressed. E-mail; fauser@gyna.azr.nl
Various new developments in clinical and basic science which may impact on IVF in the near or distant future will be
discussed in this review. These key areas include the regulation of early follicle development and the extended invitro culture of oocytes and embryos. Moreover, alternative compounds and ovarian stimulation protocols will be
discussed, along with highlights in the development of the cryopreservation of excess oocytes or embryos. Finally, the
health economics of IVF is addressed.
Keywords: cryopreservation/embryo culture/follicle development/IVF health economics/ovarian stimulation
TABLE OF CONTENTS
Introduction
Early follicle development
Oocyte/embryo culture
Ovarian stimulation protocols
Cryopreservation
Health economics of IVF
Recommendations
References
balance between success and complications and the overall
cost-effectiveness of IVF.
Areas covered in this overview include studies concerning
early pre-antral follicle development and extended in-vitro culture
of oocytes. Recent observations concerning the development of
new compounds and regimens for ovarian stimulation are also
discussed, as well as the current status of embryo cryopreservation. Finally, the health economics of IVF will be explained.
Early follicle development
Introduction
In-vitro fertilization (IVF) as practised today is complex, timeconsuming and expensive, and generates much stress, side effects
and chances for complications. Success rates have improved over
the years, with around 25% pregnancies per cycle in recent years.
Moreover, awareness is growing throughout the world that the
rate of multiple pregnanciesÐespecially triplet and higher-order
pregnanciesÐfollowing IVF can no longer be accepted (Fauser et
al., 1999). This overview will discuss several recent developments in clinical and basic science which may impact on IVF in
the near or distant future. Key issues are the development of
simpli®ed and less vigorous ovarian stimulation regimens, and
reducing the incidence of multiple pregnancies following IVF.
Certainly, these developments will ultimately improve the
The primary goal of IVF treatment is the birth of a healthy baby.
Until recently, the major focus of clinical researchers has been the
manipulation of ovarian function by exogenous FSH in an attempt
to generate as many follicles as possible. Improved understanding
of mechanisms regulating early follicle development may give
rise to more re®ned and individualized stimulation protocols.
Perhaps in the distant future, ovarian stimulation can be replaced
completely by the in-vitro maturation of oocytes. In addition,
totally new approaches for the control or enhancement of fertility
are on the horizon for future applications.
The major functional unit in the ovary is the follicle, which
consists of an oocyte surrounded by one or more layers of somatic
cells. The destiny of each follicle is determined by endocrine and
intra-ovarian factors. During normal folliculogenesis a tight
interaction exists between the oocyte and surrounding granulosa
*This review represents an overview based on lectures presented during a Round Table Conference organized by B.C.J.M.Fauser, entitled `Alternative
approaches in IVF', Lisbon, Portugal, September 2000, and sponsored by NV Organon. Invited lecturers included A.G.Byskov, A.J.Hsueh, M.M.Matzuk,
D.T.Baird, I.Boime, B.Tarlatzis, P.Barri, K.Diedrich, B.A.Lessey, J.A.Collins, J.Smitz, B.Behr, M.Plachot, M.H.E.C.Pieters, L.Hamberger and J.Shaw.
Ó European Society of Human Reproduction and Embryology
1
B.C.J.M.Fauser et al.
cells. Several distinctly different steps can be identi®ed: (i) the
initial recruitment of resting primordial follicles involved in
depletion and eventually exhaustion of the stock of follicles; (ii)
early development of pre-antral follicles, which seems to be under
the control of intra-ovarian autocrine and paracrine factors; and
(iii) the late advanced growth of antral follicles and cyclic
recruitment controlled by FSH, resulting in a limited number of
follicles which continue to grow during the follicular phase of
each menstrual cycle (see also Figure 1). These processes are
regulated differently, and hence will be discussed separately.
Initial recruitment of primordial follicles
In the human, female oogonia proliferate during early embryonic
life before differentiating into primary oocytes. The pool of
resting primordial follicles reaches its maximum size around 20
weeks of fetal life. Follicles can remain at this inactive stage for
many decades. Initial recruitment is the term indicating
primordial follicles leaving this resting pool. It is unknown as
yet whether this initiation of growth is due to reduced inhibitory
in¯uences or to direct stimulation by local intra-ovarian factors.
The potential role of the oocyte itself should also be taken into
consideration. Initial recruitment is a continuous process, and in
the human around 1000 primordial follicles start growing every
month. The morphological characteristics of follicle recruitment
include an increased size of the oocyte and a transition of
surrounding granulosa cells to a cuboid shape. In humans, it is not
known at this stage whether primordial follicles can directly
undergo atresia.
Early follicle development
Once recruited, the follicle develops through the primary and
secondary stages before an antrum is formed. Speci®c oocyte or
granulosa cell-derived factors are involved in the development of
pre-antral follicles, such as c-kit (a tyrosine kinase receptor), its
ligand, stem cell factor (for review, see McNatty et al., 1999) and
Wilms tumour 1. The involvement of androgens and the insulinlike growth factor family in early follicle development has
recently been described in the monkey model (Vendola et al.,
1999). Although some observations suggest that the process of
early follicle development is sensitive to FSH, FSH knock-out
studies (Layman and McDonough, 2000) as well as humans
Figure 1. Schematic representation of factors involved in early and late
follicle development. Adapted from McGee and Hsueh (2000).
2
presenting with defective FSH receptors or after hypophysectomy
have shown convincingly that the early stages of follicle
development remain unaffected.
Growth differentiation factor-9 (GDF-9) is a member of the
transforming growth factor b (TGF-b) super family with highest
homology to bone morphogenic protein-15 (BMP-15). This factor
is exclusively expressed in oocytes from pre-antral and early
antral follicles, and is absent from primordial follicles. GDF-9de®cient female mutant mice were infertile due to defective
follicle development. The ovaries were small, and no follicles
beyond the one-layer granulosa cell stage could be observed.
Primordial follicle numbers were clearly increased in these
animals compared with controls (Dong et al., 1996). In the
absence of GDF-9, follicles do not reach the secondary stage and
are incapable of forming multiple layers of surrounding theca
cells (Matzuk, 2000). GDF-9 also stimulates growth of pre-antral
follicles in culture (Hsueh et al., 2000). BMP-15/GDF-9 double
knock-outs also present with clearly abnormal folliculogenesis
(Yan et al., 2001). Intriguingly, Inverdale ewes which are
heterozygous for a naturally occurring X-linked mutation of the
BMP-15 gene have increased ovulation rates, while ewes that are
homozygous for this mutation develop primary ovarian failure
sheep (Galloway et al., 2000). Much attention is currently focused
towards another related factor, GDF-9B. These and other
observations demonstrate for the ®rst time that oocyte-derived
factors are required for somatic cell differentiation and interaction
with endocrine factors such as FSH.
Anti-MuÈllerian hormone (AMH), yet another member of the
TGF-b superfamily of growth and differentiation factors, is
involved in male sexual differentiation. However, mRNA for
AMH (and its type II receptor) has recently been shown to be
expressed in ovarian granulosa cells of pre-antral and small antral
follicles, suggesting a functional role. More importantly, ovaries
obtained from fertile female AMH knock-out mice had increased
numbers of pre-antral and small antral follicles, but reduced
numbers of primordial follicles, suggesting a direct or indirect
role for AMH in follicle pool depletion (Durlinger et al., 1999). It
appears likely that more oocyte or granulosa cell-derived factors
important for early folliculogenesis will be identi®ed in the near
future. These factors may represent a new avenue for the in-vitro
maturation of oocytes and for the assessment and possibly also the
manipulation of ovarian ageing.
Speci®c genes encoding for proteins involved in the initiation,
progression and completion of programmed cell death (apoptosis)
have been identi®ed in recent years. Some proteins (e.g. Bcl-2)
delay or inhibit apoptosis, whereas others (e.g. Bax) induce
apoptosis. Out of the 500 000 follicles present in the human ovary
at the beginning of reproductive life, only 400 or so reach the preovulatory stage and ovulate. Hence, follicle atresia rather than
differentiation is the fate of the great majority of female germ cells.
The magnitude of demise of follicles at early stages of
development may affect follicle pool depletion (the number of
follicles entering the growth phase) and resulting reproductive life
span. Indeed, several studies have established a correlation between
mRNA encoding for Bax and granulosa cell apoptosis. In addition,
reduced follicle loss could be observed both in mutant mice lacking
Bax, or in transgenic mice where Bcl-2 was overexpressed in the
ovary, suggesting that the life span may be extended by reducing
apoptosis (Morita et al., 1999; Perez et al., 1999).
Alternative approaches in IVF
Late follicle development
FSH acts as a survival factor for antral follicles, most of which will
undergo atresia, with only a few being rescued by the intercycle
rise in serum FSH level (also referred to as cyclic recruitment)
(Fauser and van Heusden, 1997). FSH is essential for ®nal
granulosa cell differentiation allowing for estrogen biosynthesis.
Several distinct differences between initial and cyclic recruitment can be identi®ed (McGee and Hsueh, 2000), including: (i)
differences in developmental stages of the follicle (primordial
versus large antral); (ii) oocyte status (starting to grow versus
completion of growth); (iii) regulatory factors involved (locally
derived growth factors versus FSH); and (iv) timing (continuous
throughout reproductive life versus cyclic related to the onset of a
menstrual cycle) (Otsuka et al., 2001).
Normally, only a single follicle reaches the pre-ovulatory
Graa®an stage in each cycle releasing the oocyte during
ovulation. Other follicles from the recruited cohort enter atresia,
due to insuf®cient FSH support. Only the dominant follicle
continues to grow despite decreasing FSH levels, because of its
increased FSH sensitivity along with the induction of LH
receptors on granulosa cells. Indeed, it has been shown recently
that LH can drive dominant follicle growth in the late follicular
phase (Sullivan et al., 1999).
Oocyte/embryo culture
Culture of immature oocytes
The use of elaborate media or co-culture can result in an enhanced
development of human immature oocytes in vitro (Cha et al.,
2000). However, although the resulting fertilization rates for IVF
or ICSI reach 45% and 75% respectively, implantation and
clinical pregnancy rates remain low. This mayÐamong several
other reasonsÐbe due to abnormal cytoskeletal organization
leading to mitotic spindle de®ciency and subsequently to nuclear
disorganization or chromosomal abnormalities in embryos
(Nogueira et al., 2000). Conclusions are dif®cult to draw due to
the small size of the studied series published so far, as well as the
existing differences in culture media employed, timing of oocyte
retrieval and stimulation regimes used. In addition, many
unsolved issues such as the presence of steroids in culture
medium, the signi®cance of recombinant LH, the role of
epidermal growth factor (Smitz et al., 1998) and meiosisactivating sterol (Byskov et al., 1995) as well as the importance
of metalloproteinases and the activin/inhibin system are currently
under investigation.
The in-vitro maturation of oocytes may induce permanent
changes in the expression of imprinted genes, and this may result
in abnormal fetal development (Young et al., 2001). Moreover,
the maturation systems used for human oocytes are mainly based
on animal experiments. For these reasons, the in-vitro maturation
of oocytes from small antral follicles must be regarded as an
experimental procedure which should not be applied clinically
unless its safety has been proven (Sinclair et al., 2000).
In-vitro blastocyst development
In human IVF, 80±90% of day 2±3 embryos selected for transfer
fail to survive implantation. Consequently, attempts to minimize
the chance of a twin gestation by replacing only one cleaving
embryo result in a decreased pregnancy rate per IVF cycle. By
moving the embryo transfer to the blastocyst stage (besides
achieving an improved embryo±endometrial synchrony), only
embryos with an activated embryonic genome and high developmental potential are given the chance to implant (Jones and
Trounson, 1999). In this way, a 50% implantation rate per
blastocyst (double that obtained from cleavage-stage embryos)
may be achieved, resulting in high pregnancy rates following
transfer (Behr, 1999).
By using sequential serum-free media, more than 50% of
embryos may develop into blastocysts. It should be noted,
however, that blastocyst transfer may coincide with disadvantages
such as the need for additional patient and staff education, the
requirement for more laboratory incubator space, as well as with a
5±7% risk of no development of embryos suitable for transfer at
an early stage (Gardner et al., 1998). Furthermore, a 5%
monozygotic twinning rate following blastocyst transfer has been
reported (Costa et al., 2001; Sheiner et al., 2001).
At present, patients who seem to bene®t the most from
blastocyst transfer are those who are at risk of high-order multiple
gestation, as well as those with multiple IVF failures. Among the
still unresolved issues, the value of blastocyst cryopreservation as
well as the effectiveness of a single blastocyst transfer following
pre-implantation genetic diagnosis for aneuploidy screening must
be addressed urgently. Altogether, the need for a randomized
controlled trial comparing the ef®cacy of a single day 5±6
blastocyst versus a day-3 embryo replacement in minimizing the
occurrence of a twin pregnancy is imperative. Moreover, followup studies should be performed on the health of children
conceived after blastocyst transfer.
Assessment of oocyte and embryo quality
Assessment of embryo quality has barely changed since the
beginning of IVF. The focus has been on blastomere number, size
and shape of the blastomeres, and the presence or absence of
extracellular fragments. However, as implantation and clinical
pregnancy rates in IVF are still far from optimal, the predictive
value of currently accepted morphological criteria applied to day
2±3 embryos has been questioned. In fact, embryos considered to
be unsuitable for embryo transfer on days 2±3 of culture are able
not only to develop to blastocysts in vitro (Rijnders and Jansen,
1998), but also to implant following transfer to the uterus.
Conversely, many of the morphologically optimal embryos on
days 2±3 of culture may fail to develop to blastocyst stage, while
a signi®cant proportion of them are chromosomally abnormal
(Plachot et al., 1987; Munne and Cohen, 1998). It appears that the
developmental history of the embryo may also be used as a
marker predicting chances of implantation (van Royen et al.,
2001). A close relationship exists between blastocyst quality and
success of transfer (Gardner et al., 2000). The blastocyst grading
system is based on the degree of expansion of the blastocyst
cavity, the inner cell mass (potential embryonic cells) and the
trophectoderm (potential placental cells). A fully expanded
blastocyst with numerous tightly packed inner cells and many
cohesive cells within the trophectoderm is thought to be optimal
for implantation. It should be noted, that the development of an
embryo to the blastocyst stage is not a con®rmation of
chromosomal normality, as at least 10% of blastocysts are
chromosomally abnormal (unpublished data).
3
B.C.J.M.Fauser et al.
The evaluation of oocyte quality has attracted less attention in
conventional IVF, as the precise assessment of nuclear maturity is
not easy to perform (due to the presence of surrounding cumulus
cells). Attempts to grade cumulus±oocyte complexes morphologically show only weak correlation with the real maturity of
oocytes. Metaphase II oocytes can only be assessed after the
removal of cumulus cells by hyaluronidase, as is performed in
ICSI cycles. IIIt is generally accepted that good quality human
metaphase II oocytes should have a clear moderately granular
cytoplasm, a small perivitelline space and a clear, colourless zona
pellucida. However, oocytes deviating from the ideal morphotype
may have a normal capacity for fertilization and embryo
development following ICSI. The so-called ideal oocytes may
represent only 34% of all those retrieved.
It is important to de®ne the developmental potential of embryos
originating from morphologically abnormal oocytes by conducting
large studies which relate oocyte morphology to the outcome of
ICSI. Moreover, the evaluation of embryo morphology needs to be
readdressed, asÐdepending on maternal ageÐbetween 20
and 50% of morphologically normal embryos appear to be
chromosomally aberrant (Gianaroli et al., 2001; Sandalinas et
al., 2001).
Ovarian stimulation protocols
The key issues related to ovarian stimulation and drugs used for
that purpose remain maximal ef®cacy with minimal chances for
ovarian hyperstimulation syndrome (OHSS) and the avoidance of
multiple gestations. Clearly, agreement exists that multiple
pregnancy can be largely avoided by replacing only a single
embryo. In Europe there is a clear trend to limit replacement to
two embryos, thereby restricting the problem of multiple
pregnancies to twins. The major problem related to single embryo
transfer remains judgement of the quality of embryos. It should be
noted that a pregnancy rate per cycle of approximately 10% is
accepted by the scienti®c community for in-vivo ovulation
induction, whereas the same rate for IVF procedures is considered
too low. Simpli®cation of IVF procedures by using GnRH
antagonists may increase the acceptability of a relatively low
pregnancy rate following single embryo transfer.
The single most important issue related to ovarian stimulation
remains the avoidance of life-threatening OHSS. Less vigorous
stimulation of the ovaries (referred to as soft protocols or minimal
hyperstimulation) (Fauser et al., 1999) may help to achieve this
goal. The price to pay is an increased percentage of cycles with low
or no response. Furthermore, OHSS is only partially related to the
dose of the drugs used to stimulate the ovary. The individual
sensitivity of the patient to FSH stimulation may be more important
(Fauser and van Heusden, 1997). The introduction of GnRH
antagonists may also reduce the risk of OHSS. Because of the
competitive mechanism of action of antagonists, HCG for ®nal
oocyte maturation may be replaced by a single injection of a GnRH
agonist. Data supporting the signi®cant reduction in the risk of
developing OHSS by replacing HCG with a GnRH agonist have
not yet gained suf®cient attention (Itskovitz et al., 1991).
Drugs and protocols for ovarian stimulation
Few prospective randomized studies have been performed
concerning drugs and protocols for ovarian stimulation. Even
4
some of those studies have problems, including: (i) too few
patients treated to reach suf®cient statistical power; (ii) the use of
surrogate endpoints such as the number of oocytes and embryos
rather than the single most relevant clinical endpoint (viable
pregnancies resulting in live birth); and (iii) the application of
rigid regimens in highly selected patient groups. It is rather
surprising that de®nite conclusions are frequently drawn from
inadequate studies. Although less satisfying for the individual
investigator, fewer but larger studies in unselected patient
populations focusing on viable pregnancy rates are needed.
New treatment protocols for IVF have become possible due to
the recent introduction of two comparable GnRH antagonist
compounds, cetrorelix and ganirelix. Both multiple and singledose regimens are effective in preventing a premature LH rise
(Bouchard and Fauser, 2000). In contrast to the widely used
GnRH agonist long protocol, the antagonist is started several days
after the initiation of exogenous FSH. These regimens are much
shorter and not complicated by chances of cyst formation due to
the GnRH agonist `¯are' effect. Furthermore, the use of
antagonists reduces the required total dose of FSH by approximately 20%. Surprisingly, initial clinical studies applying GnRH
antagonists showed a somewhat lower vital pregnancy rate
(Bouchard and Fauser, 2000), but a learning curve for the
clinician may be the most likely explanation for this ®nding.
However, the possibility of a relative overdose of the antagonistÐ
especially in low bodyweight womenÐshould also be considered.
Several studies have suggested that extremely low late follicular
phase LH levels are detrimental for IVF outcome (Westergaard et
al., 2000; Filicori and Cognigni, 2001). Since the GnRH
antagonists have become available, discussion concerning the
use of a natural unstimulated cycle for IVF has re-emerged. It is
possible to manipulate the LH surge during the development of a
spontaneously growing single follicle by delaying this surge with
a GnRH antagonist. The disadvantage remains the availability of
one oocyte only, resulting in relatively low pregnancy rates.
Moreover, since the introduction of GnRH antagonists the
possible use of clomiphene citrate has again been suggested.
The debate concerning the comparison of clinical outcome
following the use of recombinant versus urinary FSH continues.
There is no question that recombinant FSH is more pure and is
synthesized more consistently (resulting in reduced batch-to-batch
variability), without any risk of contamination. Recombinant FSH
products have been shown by prospective studies to result in a
small but signi®cantly higher viable pregnancy rate compared
with different urinary FSH preparations (Daya and Gunby, 1999),
though the difference is only ~5%. The counter-argument used by
those favouring the use of urinary FSH relates to the difference in
price, although this economic argument should be judged in the
light of the total cost of the treatment per cycle. New
gonadotrophin drugs will become available, such as short- and
long-acting FSH that have half-lives of about 0.5 and 4 days
respectively. Long-acting FSH may also be achieved with
chimeric molecules such as FSH-CTP (where the carboxyterminal part of HCG, which is responsible for its long half-life,
is combined with the FSH-b chain) (Bouloux et al., 2001).
Standard FSH regimens in combination with GnRH agonists
include the long, short and ultra-short protocols. In general, the
long protocol, starting with GnRH agonist treatment in the luteal
phase of the preceding cycle, is preferred due to a small but
Alternative approaches in IVF
signi®cant increase in vital pregnancy rate as shown by metaanalysis (Daya, 2000).
Fixed, incremental and decremental FSH dose regimens are used
without clear evidence of major differences in either outcome or
side effects. The starting dose of FSH appears to be higher in the
USA (225±300 IU/day) compared with elsewhere (150±225 IU/
day). The higher starting dose results in signi®cantly more oocytes
and OHSS, and a lower chance of cancellation due to absent or low
response. Although kinetic data of FSH show an inverse relationship between serum FSH concentrations and body weight, it is
rather surprising that body weight is not used to titrate the starting
dose. During recent years a debate has continued on less vigorous
ovarian stimulation, described as minimal stimulation or soft/mild
protocols. In principle, this can be achieved by either using a lower
daily dose of FSH with a more careful dose increase, and/or by
starting FSH treatment later in the cycle in case short or ultra-short
GnRH agonist protocols or GnRH antagonist are applied. Such
mild protocols are expected to decrease the incidence ofÐbut not
eliminateÐOHSS because the individual ovarian sensitivity is at
least as important as the FSH dose. The disadvantages of soft
protocols will be a lower number of oocytes and a higher incidence
of cancelled cycles.
The induction of oocyte maturation
A very important unsolved problem related to ovarian
stimulation for IVF is the quality of the oocyte. As oocyte quality
is a decisive factor for embryo quality and the resultant pregnancy
rate, there is an urgent need to develop new methods for better
judgement of oocyte and/or embryo quality, as discussed earlier.
The extension of in-vitro embryo culture up to the blastocyst stage
will eliminate some inferior embryos with genetic or other
developmental abnormalities, but certainly not all. Improved
embryo or oocyte selection seems to be crucial in order to embark
upon single embryo transfer and less vigorous ovarian stimulation.
To resume meiosis and induce luteinization in IVF protocols,
urinary HCG at a dose of 5000±10 000 IU has been the standard
treatment for many years. New developments in this area are the
availability of recombinant LH and HCG. When exogenous LH is
used to mimic the LH surge, two injections with a 1-day interval
may be required (Loumaye et al., 1999) due to the short half-life of
LH (10±20 min). GnRH antagonists provide another new
opportunity to replace HCG since the mode of action of the
antagonists is competitive. Instead of GnRH agonists downregulating and internalizing receptors, they can be used to replace
HCG by using the initial gonadotrophin stimulatory `¯are' effect.
Recent evidence suggests that the use of a GnRH agonist in this
way may avoid OHSS in case too many follicles are developing,
combined with an unchanged reproductive potential of the oocytes
obtained. An alternative solution to solve the problem of imminent
OHSS due to abundant follicular development is to switch to a
(high-dose) GnRH antagonist (de Jong et al., 1998), though the
latter approach implicates loss of the cycle for IVF.
Cryopreservation
Oocyte cryopreservation
The cryopreservation of supernumerary embryos increases the
chance of obtaining a pregnancy from a single IVF cycle. Frozen
embryo storage can give rise to ethical and legal problems which
could be bypassed in case oocytes might be cryopreserved in a
reliable manner. Gamete cryopreservation can also be important
in the case of cancer therapy to preserve the chance of
reproduction. While human embryo cryopreservation is now
routine, it remains a research procedure for oocytes (Mandelbaum
et al., 1998).
The problems associated with cryopreservation of the
mature oocyte are related to its large volume, and to the fact
that it is a very specialized cell. The freezing process must
not only maintain the cellular viability, but the potential for
fertilization and subsequent embryo development must also be
preserved. Several anomalies have been reported following
cryopreservation, including abnormalities of the zona pellucida,
induction of parthenogenetic activation and, more importantly,
meiotic spindle anomalies. The ef®ciency of oocyte cryopreservation expressed as the number of children born per
frozen±thawed oocyte is <1%. Whilst anomalies of the zona
pellucida might be overcome through the use of ICSI, spindle
anomalies could be overcome by freezing at the GV stage.
Nevertheless, optimal culture conditions for the maturation of
GV oocytes have not yet been established. Meiotic spindle
anomalies might also be avoided by using vitri®cation
techniques (Le Gal and Massip, 1999). By doing so, the
problem of chilling sensitivity of the meiotic spindle after
slow cooling of oocytes can be avoided. The safety and
ef®cacy of vitri®cation techniques is yet to be determined,
however (Chen et al., 2000).
Cryopreservation of ovarian tissue
One of the chief attractions of storing ovarian tissue is that some
of the problems associated with cryopreservation of mature or
immature oocytes are circumvented. Primordial follicles contain
an oocyte that is much smaller than the mature cell, and they
appear to be more tolerant to freezing and thawing. The small size
of primordial follicles, the absence of zona pellucida, the low
number of support cells, its low metabolic rate, the arrest at
prophase I of meiosis, the small amounts of chilling-sensitive
lipids present and the lack of cortical granules make the
primordial follicle less sensitive to cryoinjury than a mature
oocyte (Shaw et al., 2000).
Very small pieces of ovarian tissue must be used for
optimal effectiveness. However, the problem with this
approach is that the restoration of fertility depends on the
re-implantation of ovarian tissue either to the same person or
to an immunologically compatible recipient. When the ovary
has been removed for reasons of cancer, the risk of reimplanting cancerous cells is present (Shaw et al., 1996). An
alternative is that early-stage follicles could be cultured
through the stages where it is possible to mature and fertilize
the oocyte in vitro. At present, however, ovarian tissue
cryopreservation, the re-implantation, and the culture of earlystage follicles are still at the experimental stage
Cryopreservation of human embryos
There are three main reasons to cryopreserve embryos for thawing
and transfer at a later date. The ®rst reason is that the current use
of ovarian stimulation regimens yields a high number of oocytes
which can be fertilized. In order to reduce the number of multiple
5
B.C.J.M.Fauser et al.
births, most IVF clinics transfer (maximally) two to three goodquality embryos, with supernumerary embryos being frozen,
stored and used in subsequent cycles. As a result, more than one
transfer from a single stimulation cycle can be performed, thereby
increasing the overall chance of pregnancy. The second reason is
the availability of embryo cryopreservation, which allows embryo
transfer to be delayed for those women who are at risk of
developing severe OHSS. The ®nal reason is that donated
embryos can be frozen to eliminate the need for synchronization
of the donor and recipient cycles; moreover, the donated frozen
embryos can be held in quarantine until screening for transmissible viruses has been completed. The importance of human
embryo cryopreservation will vary from centre to centre, and will
also depend on the embryo cryopreservation criteria that each
centre will develop.
It would be highly desirable, as has been suggested previously
(Jones et al., 1995), to establish a method that would allow not only
a correct evaluation of the cryopreservation of human embryos per
se, but also an evaluation of the role of embryo cryopreservation in
enhancing the total reproductive potential of a single treatment
cycle and the possibility of comparing the cryopreservation of
embryos between different centres. The embryologist/clinician
requires three main types of information concerning the different
variables of freezing and thawing. First, the percentage of patients
with a fresh transfer who also have material available for
cryopreservation (cycle cryopreservation rate), and the percentages of embryos assigned to fresh transfer (embryo transfer rate)
and to cryopreservation (embryo cryopreservation rate) is required.
Second, the percentage of embryos that survive the freezing±
thawing process and the pregnancy potential of the surviving
embryo is needed. As a result, the best way to report results of
freeze±thawing human embryos would be as the number of
children born per frozen and thawed embryo. Third, the
contribution of the results of cryopreservation to the total
pregnancy potential of the oocyte collection cycle would be
required.
A formula has been proposed (Testart, 1988) to compare the
success rate of IVF according to various parameters, including the
policy for embryo cryopreservation. This formula would enable all
IVF teams to present their data in an identical manner. Taken
together, we feel that these suggestions (Testart, 1988; Jones et al.,
1995) should become common practice when reporting cryopreservation data, and in this way over- or underestimations of the
importance of human embryo cryopreservation could be avoided.
Moreover, the exact role of human embryo cryopreservation in the
entire infertility treatment could be more correctly estimated.
There are two main strategies for cryopreserving human
embryos. The ®rst strategy involves selecting embryos for fresh
transfer and for cryopreservation before morphology becomes a
substantial factor. Freezing is then performed at the two
pronuclear (2PN) stage. There are several advantages when
freezing 2PN embryos: (i) it is more acceptable for some persons
with ethical problems; (ii) the cell is at interphase of mitotic
division; (iii) there are no anucleate fragments present (this is
known to be negatively correlated with cryopreservation outcome); and (iv) 2PN freezing is a good alternative in case of
suboptimal culture conditions. In some countries, freezing at the
2PN stage is required by law. The disadvantages of 2PN embryo
freezing are that, despite optimized evaluation techniques for 2PN
6
embryos, it is dif®cult to choose the embryos for fresh transfer. As
a result, the fresh cycle is not optimized. Another disadvantage is
that a situation may arise in which the zygotes left in culture for
fresh transfer do not cleave further.
The second strategy involves optimizing fresh transfer, thereby
allowing the morphologically best embryos to be transferred
fresh. Embryos can be frozen at the 2- to 8-cell stage and at the
blastocyst stage. The advantage of 2- to 8-cell stage freezing is
that embryos can be selected for transfer, and that the cleavage
potential of remaining embryos can be established before
freezing. A good selection is possible for embryo transfer in the
collection cycle and for freezing of supernumerary embryos since
the potential of embryos to cleave is ascertained. Consequently, it
is often necessary to freeze a cohort of embryos at different
developmental stages and of different morphological qualities. As
a result, it is more dif®cult to keep the embryos 100% intact after
thawing, and damaged blastomeres coexist with undamaged ones
on a regular basis.
An even better selection for embryos to be frozen involves
freezing at the blastocyst stage. Blastocysts can lose some
trophectoderm cells due to freezing without viability loss (Veiga
et al., 1997). There is also a better synchronization of embryonic
stage and uterine endometrial development. Recent improvements
in culture media make it possible to obtain high rates of blastocysts
without co-culture. Transfer of fresh blastocysts seems to produce
high implantation rates; hence blastocyst freezing may become the
preferred method for preserving human embryos.
When comparing 2PN, multicellular and blastocyst freezing it
is dif®cult to provide conclusive data on the eventual superiority
of one of the protocols. It is both clear and important that the
cycle cryopreservation rate and the embryo cryopreservation rate
will differ depending on whether embryos are frozen at the
zygote, multicellular or blastocyst stage. The stage of cryopreservation will also in¯uence the number of embryos that are
frozen, as well as the implantation rate per embryo transferred
(which varies from 6 to 13%) (Veeck et al., 1993; Kaufman et al.,
1995; Mandelbaum et al., 1998; A.van Steirteghem, unpublished
data). The reasons for the different cryobiological behaviour
between blastocysts obtained using different culture systems need
to be clari®ed (MeÂneÂzo et al., 2000). Nowadays, fresh blastocyst
transfer leading to the transfer of one viable blastocyst or transfer
of one top-quality 8-cell embryo to avoid multiple pregnancies at
all costs is considered by some patients. Before such a strategy is
offered to the patients it must be proven that freezing supernumerary embryos or blastocysts is a reliable and safe procedure.
Follow-up of children after cryopreservation
In the total cohort of children (aged up to 18 months) conceived
from cryopreserved embryos, no differences were found in major
pathological features compared with children conceived from fresh
embryos or with those conceived spontaneously (Wennerholm et
al., 1997, 1998). Minor handicaps, behavioural disturbances,
learning dif®culties and dysfunction of attention cannot be ruled
out at this age. It has also been shown that cryopreservation of
mouse embryos induced some long-term effects (Dulioust et al.,
1995), although the methodology of this study was criticised. As a
result, long-term follow-up studies are needed in order to prove the
safety of freezing±thawing processes in IVF.
Alternative approaches in IVF
Health economics of IVF
Health economics comprises more than a simple comparison of
costs and effects, although these might be the two factors most
easily taken into account. In a economic analysis, differentiation
should be made between direct costs (consultations, personnel,
equipment, drugs, complications, monitoring frequency) and
indirect costs (travel, time off work, lost wages, long-term
complications such as OHSS and multiple pregnancies, and
obstetric and neonatal care). The effects, in the case of IVF,
consist predominantly of outcome (pregnancy or live birth). Apart
from these, patient characteristics, the patient's appreciation of a
pregnancy and preferences for treatment and emotional distress are
important but dif®cult to weigh (Ryan, 1999). It is even more
dif®cult to include eventual savings and bene®ts to patients and
society into the equation. Well-de®ned, objective and clinically
relevant endpoints (such as singleton live births per started
treatment, or per patient) should be employed and the background
treatment-independent pregnancy chance should be taken into
account.
Direct costs
Direct procedure costs per IVF cycle vary considerably from
country to country, and can be high (e.g. $1000 in Ireland, $2500 in
Japan, $4000 in Lebanon and $8000 in the USA). No evidence has
been found that the success rate of IVF correlates with the cost. In
the USA, the cost per delivery has been calculated as $66 667 for
the ®rst treatment cycle and $114 286 for the sixth cycle (Neumann
et al., 1994). In Scandinavia (direct cost per procedure $4000), the
cost per delivery is $15 540 (Granberg et al., 1998). The calculated
direct costs of infertility care in the UK are listed in Table I (Philips
et al., 2000). It has been shown that if only 6% of all infertile
couples required IVF, then in a group of 100 couples the cost of
infertility diagnosis would be $76 993, the cost of IVF $71 820, and
the combined costs of all other infertility treatments would be
$127 991 (Collins et al., 1997). Hence, the cost of IVF treatment in
six couples among a group of 100 infertile couples is equal to the
costs of infertility diagnosis in the entire group.
A full economic evaluation requires a randomized comparison
of alternative interventions with respect to both costs and
outcomes. Only two such studies have been published. In the
®rst study (Karande et al., 1999), IVF was compared with
standard therapy and the incremental cost calculated. The
procedure cost was $13 255 for IVF and $9557 for standard
therapy, and the pregnancy rates were 34.8 and 56.0% per couple
Table I. Cost of infertility services in the United Kingdom (US$)
Procedure
Cost per cycle
Cost per delivery
Clomiphene
Surgery
HMG/IUI
Donor insemination
IVF/ICSI
IVF
3
1163
327
186
1454
1202
18
11 634
1636
2478
4691
5008
Adapted from Appendix for UK expected treatment costs provided by
Philips et al. (2000).
IUI = intra-uterine insemination.
respectively. Hence, this study clearly favours the current
standard infertility algorithm over IVF, the marginal cost being
$17 300 less per additional pregnancy with standard care
compared with IVF. In the second study, which was conducted
in the Netherlands (Goverde et al., 2000), IVF was compared with
intra-uterine insemination (IUI) in a spontaneous cycle, and with
IUI in a cycle with controlled ovarian stimulation (75 IU FSH).
These authors reported procedure costs of $1650, $446 and $298
for IVF, IUI + FSH and IUI respectively. The generalizability of
this study has been criticised because the low IVF pregnancy rate
(33/270; 12.2%) per cycle, and the high IUI pregnancy rate in
spontaneous (i.e. unstimulated) cycles (25/338; 7.4%) appear
atypical. The marginal cost per additional pregnancy by IVF over
IUI in a spontaneous cycle was $42 972 per couple. This study,
with an IVF success rate which is at least realistic in some areas
of the spectrum of severity of infertility problems, illustrates that
the marginal bene®ts of IVF over IUI are expensive. The study
also shows that IVF in the real world involves patients' choice:
although they were offered six cycles of either IUI or IVF free of
charge, the patients elected to have only four and three cycles
respectively, which impacted on the pregnancy rate per couple.
Indirect costs
An important part of the indirect costs of IVF is determined by
multiple pregnancies. The projected delivery and neonatal costs
of multiple pregnancy deliveries in the USA for the year 2000 are
$51 715 for twins, $149 598 for triplets and $247 482 for
quadruplets, compared with $9000 for singletons. This would
lead to $639 million due to multiple pregnancy care compared
with $470 million for the combined direct costs of all IVF and
ICSI procedures in the USA (Collins and Graves, 2000). If a
policy to transfer only two embryos were to be adopted, the total
costs would decrease from $1110 million to $863 million ($470
million direct IVF/ICSI costs, $393 million additional multiple
pregnancy care costs) and to $470 million if elective single
embryo transfer were to be adopted as a general policy. These
authors thus demonstrated that the neonatal cost of IVFassociated multiple pregnancy is 36% more than the direct cost
of the IVF procedure. The childhood healthcare and educational
costs of pre-term birth add to the multiple pregnancy costs.
Preventing multiple pregnancies would save enough money to
pay for all IVF procedures in the USA.
The relationship between IVF supply and demand depends in
part on a hypothetical estimate of the demand or need for IVF
cycles. If standard treatment could provide 40% of all infertility
couples with a pregnancy, and if 5% would need IVF/ICSI for
bilaterally occluded tubes and another 5% for severe oligozoospermia, then 50% would qualify for IVF because of persistent
infertility. Furthermore, if 10% of the population consisted of
married or cohabiting women aged 18±44 years, and if 10% of
these (i.e. 1% of the population) had a fertility problem, then
10 000 women per 1 million population would need infertility
diagnosis and treatment. Assuming that only half of them would
in fact seek infertility care, this would mean 5000 infertile couples
per million population. Of these couples, 2500 would qualify for
IVF because of persistent infertility and 500 because of severe
tubal or male factor infertility. If only half of these were to accept
IVF, the assumed need for IVF resources would be at least 1500
procedures per annum per million population.
7
B.C.J.M.Fauser et al.
Table II. IVF availability: cycles performed per annum per million population
No. of cycles
<100
100 to 499
500 to 999
>1000
Austria, Egypt, Italy, Kazachstan
Latin America, Poland, Russia, Spain
Thailand, Turkey
Belgium, Canada, Czech Rep., Germany
Greece, Hong Kong, Hungary, Ireland
Japan, Korea, Singapore, Slovenia
Switzerland, Taiwan, UK, USA
Australia/NZ, Denmark, Finland, France
Iceland, Netherlands, Norway, Sweden
Israel
The availability of IVF in cycles per million population per
year in 35 countries reporting suf®ciently detailed ®gures to
calculate IVF availability is shown in Table II. It is clear that
supply and demand of IVF services are not in balance in the vast
majority of these countries. There are more IVF centres in
countries with higher-quality national health programmes, and in
countries with more public spending on healthcare. In many
countries the IVF cost per cycle represents a substantial portion of
the Gross Domestic Product per capita. Thus, each cycle of IVF
represents a large portion of average family income per annum.
The average couple would have to spend 10±20% of their annual
family income on one or more IVF attempts.
Recommendations
Many challenges to make signi®cant improvements in IVF have
appeared to emerge. However, caution should be shown with the
premature clinical introduction of new strategies before their
ef®cacy and safety have been established convincingly. The
following statements may summarize different topics covered in
the current review:
1. The improved understanding of mechanisms regulating early
follicle development may give rise to re®ned, individualized
ovarian stimulation protocols. Eventually, ovarian stimulation
may be replaced by the in-vitro maturation of oocytes. However,
series published to date are extremely small, and the safety of this
procedure remains to be established.
2. Implantation rates per embryo transferred and resulting
clinical pregnancy rates after IVF are still far from optimal. The
evaluation of embryo quality may improve with extended embryo
culture, but further studies in unselected patient groups are
urgently needed.
3. Subtle ovarian stimulation protocols along with a reduction
in the number of embryos transferred also seem crucial steps for
the improvement of ef®cacy and safety of IVF. Moreover, the
exact role of embryo cryopreservation in enhancing the total
reproductive potential of a single treatment cycle should be
assessed in a more objective and reproducible manner.
4. Caution should be shown in the interpretation of clinical
studies employing surrogate endpoint parameters such as the
number of oocytes retrieved or implantation rates per embryo
transferred. IVF outcome should be expressed as (singleton) live
births per started treatment, and the study group involved should be
representative and clearly described. There is a great need for
randomized controlled trials to compare outcome and costs of
standard IVF with alternative interventions in a full economic
evaluation.
8
5. In developed nations, IVF utilization is far below the
estimated need among infertile couples, principally because of the
high cost. The major cost components are the price of ovarian
stimulation drugs, cycle monitoring and multiple pregnancy
deliveries. More conservative ovarian stimulation drugs and
restrained embryo transfer protocols would reduce the overall cost
of IVF and facilitate the extension of this substantial health
bene®t to more infertile couples in all countries.
References
Behr, B. (1999) Blastocyst culture and transfer. Hum. Reprod., 14, 5±6.
Bouchard, B. and Fauser, B.C. (2000) Gonadotropin-releasing hormone
antagonist: new tools vs. old habits. Fertil. Steril., 73, 18±20.
Bouloux, P.M., Handelsman, D.J., Jockenhovel, F. et al. (2001) First human
exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Hum.
Reprod., 16, 1592±1597.
Byskov, A.G., Andersen, C.Y., Nordholm, L. et al. (1995) Chemical structure
of sterols that activate oocyte meiosis. Nature, 374, 559±562.
Cha, K.Y., Han, S.Y., Chung, H.M. et al. (2000) Pregnancies and deliveries
after in vitro maturation culture followed by in vitro fertilization and
embryo transfer without stimulation in women with polycystic ovary
syndrome. Fertil. Steril., 73, 978±983.
Chen, S.U., Lein, Y.R., Chao, K.H. et al. (2000) Cryopreservation of mature
human oocytes by vitri®cation with ethylene glycol in straws. Fertil.
Steril., 74, 804±808.
Collins, J.A. and Graves, G. (2000) The economic consequences of multiple
gestation pregnancy in assisted conception cycles. Hum. Fertil., 3, 275±283.
Collins, J.A., Feeny, D. and Gunby, J. (1997) The cost of infertility diagnosis
and treatment in Canada in 1995. Hum. Reprod., 12, 951±958.
Da Costa, A.L., Abdelmassih, S., de Oliviera, F.G. et al. (2001) Monozygotic
twins and transfer at the blastocyst stage after ICSI. Hum. Reprod., 16,
333±336.
Daya, S. (2000) GnRH agonist protocols for pituitary desensitization in in
vitro fertilization and gamete intrafallopian transfer cycles. Cochrane
Database Syst. Rev., CD001299
Daya, S. and Gunby, B. (1999) Recombinant versus urinary FSH for ovarian
stimulation in assisted reproduction. Hum. Reprod., 14, 2207±2215.
De Jong, D., Macklon, N.S., Mannaerts, B.M., Coelingh Bennink, H.J. and
Fauser, B.C. (1998) High dose GnRH antagonist may prevent OHSS
caused by ovarian stimulation for IVF. Hum. Reprod., 13, 573±575.
Dong, J., Albertini, D.F., Nishimori, K. et al. (1996) Growth differentiation
factor-9 is required during early ovarian folliculogenesis. Nature, 383,
531±353.
Dulioust, E., Toyama, K., Busnel, M. et al. (1995) Long-term effects of
embryo freezing in mice. Proc. Natl Acad. Sci. USA, 92, 589±593.
Durlinger, A.L., Kramer, P., Karels, B. et al. (1999) Control of primordial
follicle recruitment by anti-Mullerian hormone in the mouse.
Endocrinology, 140, 5789±5796.
Fauser, B.C. and van Heusden, A.M. (1997) Manipulation of human ovarian
function: physiological concepts and clinical consequences. Endocr. Rev.,
18, 71±106.
Fauser, B.C., Devroey, P., Yen, S.S. et al. (1999) Minimal ovarian stimulation
for IVF: appraisal of potential bene®ts and drawbacks. Hum. Reprod., 11,
2681±2686.
Filicori, M. and Cognigni, G.E. (2001) Clinical review 126: roles and novel
regimens of luteinizing hormone and follicle-stimulating hormone in
ovulation induction. J. Clin. Endocrinol. Metab., 86, 1437±1441.
Alternative approaches in IVF
Galloway, S.M., McNatty, K.P., Cambridge, L.M. et al. (2000) Mutation in an
oocyte-derived growth factor gene (BMP15) cause increased ovulation rate
and infertility in a dosage-sensitive manner. Nature Genet., 25, 279±283.
Gardner, D.K., Schoolcraft, W.B., Wagley, L. et al. (1998) A prospective
randomized trial of blastocyst culture and transfer in in-vitro fertilization.
Hum. Reprod., 13, 3434±3440.
Gardner, D.K., Lane, M., Stevens, J. et al. (2000) Blastocyst score affects
implantation and pregnancy outcome: towards a single blastocyst transfer.
Fertil. Steril., 73, 1155±1158.
Gianaroli, L., Magli, M.C. and Ferraretti, A.P. (2001) The in vivo and in vitro
ef®ciency and ef®cacy of PGD for aneuploidy. Mol. Cell. Endocrinol.,
183 (Suppl.), S13±S18.
Goverde, A.J., McDonnell, J., Vermeiden, J. et al. (2000) Intrauterine
insemination or in-vitro fertilisation in idiopathic subfertility and male
subfertility: a randomised trial and cost-effectiveness analysis. Lancet, 1,
13±18.
Granberg, M., Wikland, M. and Hamberger L. (1998) Financing of IVF/ET in
the Nordic countries. Acta Obstet. Gynecol. Scand., 77, 63±67.
Hsueh, A.J., McGee, E.A., Hayashi, M. et al. (2000) Hormonal regulation of
early follicle development in the rat ovary. Mol. Cell. Endocrinol., 163,
95±100.
Itskovitz, J., Boldes, R., Levron, J., Yohanan, E., Kahana, L. and Brandes, J.
(1991) Induction of preovulatory LH surge and prevention of ovarian
hyperstimulation syndrome by GnRH agonist. Fertil. Steril., 56, 213±220.
Jones, G.M. and Trounson, A.O. (1999) Blastocyst stage transfer: pitfalls and
bene®ts. The bene®ts of extended culture. Hum. Reprod., 14, 1405±1408.
Jones, H., Veeck, L. and Muascher, S. (1995) Cryopreservation: the problem
of evaluation. Hum. Reprod., 10, 2136±2138.
Karande, V.C., Korn, A., Morris, R.N., Rao, R., Balin, M., Rinehart, J., Dohn,
K. and Gleicher, N. (1999) Prospective randomized trial comparing the
outcome and cost of in vitro fertilization with that of a traditional
treatment algorithm as ®rst-line therapy for couples with infertility. Fertil.
Steril., 71, 468±475.
Kaufman, R., MeÂneÂzo, Y., Hazout, A. et al. (1995) Cocultured blastocyst
cryopreservation: experience of more than 500 transfer cycles. Fertil.
Steril., 64, 1125±1129.
Layman, L.C. and McDonough, P.G. (2000) Mutations of follicle-stimulating
hormone-beta and its receptors in human and mouse: genotype/phenotype.
Mol. Cell. Endocrinol., 161, 9±17.
Le Gal, F. and Massip, A. (1999) Cryopreservation of cattle oocytes: effects of
meiotic stage, cycloheximide treatment, and vitri®cation procedure.
Cryobiology, 38, 290±300.
Loumaye, E., Piazzi, A. and Engrand, P. (1999) The use of rec LH, GnRH
agonist or hCG to trigger ovulation. In: Shoham, Z., Collins, C.M. and
Jones, H.S. (eds), Female Infertility Therapy Current Practice. Martin
Dunitz, London, pp. 125±135.
Mandelbaum, J., Belaisch-Allart, J., Junca, A. et al. (1998) Cryopreservation
in human assisted reproduction is now routine for embryos but remains a
research procedure for oocytes. Hum. Reprod., 13, 161±177.
Matzuk, M.M. (2000) Revelations of ovarian follicle biology from gene knock
out mice. Mol. Cell. Endocrinol., 163, 61±66.
McGee, E.A. and Hsueh, A.J. (2000) Initial and cyclic recruitment of ovarian
follicles. Endocr. Rev., 21, 200±214.
McNatty, K.P., Heath, D.A., Lundy, T. et al. (1999) Control of ovarian
follicular development. J. Reprod. Fertil., 54, 3±16.
MeÂneÂzo, Y., Veiga, A. and Pouly, J. (2000) Assisted reproductive technology
(ART) in humans: facts and uncertainties. Theriogenology, 53, 599±610.
Morita, Y., Perez, G.I., Maravei, D.V. et al. (1999) Targeted expression of
Bcl-2 in mouse oocytes inhibits ovarian follicle atresia and prevents
spontaneous and chemotherapy-induced oocyte apoptosis in vitro. Mol.
Endocrinol., 13, 841±850.
MunneÂ, S. and Cohen, J. (1998) Chromosome abnormalities in human
embryos. Hum. Reprod. Update, 4, 842±855.
Neumann, P.J., Gharib, S.D. and Weinstein, M.C. (1994) The cost of a successful
delivery with in vitro fertilization, N. Engl. J. Med., 331, 239±243.
Nogueira, D., Staessen, C., Van de Velde, H. et al. (2000) Nuclear status and
cytogenetics of embryos derived from in vitro-matured oocytes. Fertil.
Steril., 74, 295±298.
Otsuka, F., Moore, R.K. and Shimasaki, S. (2001) Biological function and
cellular mechanism of bone morphogenetic protein-6 in the ovary. J. Biol.
Chem., 276, 32889±32895.
Perez, G.I., Robles, R., Knudson, C.M. et al. (1999) Prolongation of ovarian
lifespan into advanced chronological age by Bax-de®ciency. Nature
Genet., 21, 200±203.
Philips, Z., Barraza-Llorens, M. and Posnett, J. (2000) Evaluation of the
relative cost-effectiveness of treatments for infertility in the UK. Hum.
Reprod., 15, 95±106.
Plachot, M., de Grouchy, J., Junca, A.M. et al. (1987) From oocyte to embryo:
a model, deduced from in vitro fertilization, for natural selection against
chromosome abnormalities. Ann. Genet., 30, 22±32.
Rijnders, P.M. and Jansen, C.A. (1998) The predictive value of day 3 embryo
morphology regarding blastocyst formation, pregnancy and implantation
rate after day 5 transfer following in-vitro fertilization or intracytoplasmic
sperm injection. Hum. Reprod., 13, 2869±2873.
Ryan, M. (1999) Using conjoint analysis to take account of patient preferences
and go beyond health outcomes: an application to in vitro fertilization.
Social Sci. Med., 48, 535±546.
Sandalinas, M., Sadowy, S., Alikani, M., Calderon, G., Cohen, J. and MunneÂ,
S. (2001) Developmental ability of chromosomally abnormal human
embryos to develop to the blastocyst stage. Hum. Reprod., 16, 1954±1958.
Shaw, J.M., Bowles, J., Koopman, P., Wood, E.G. and Trounson, A.O. (1996)
Fresh and cryopreserved ovarian tissue samples from donors with
lymphoma transmit the cancer to graft recipients. Hum. Reprod., 11,
1668±1673.
Shaw, J., Oranratnachai, A. and Trounson, A. (2000) Fundamental
cryobiology of mammalian oocytes and ovarian tissue. Theriogenology,
53, 59±72.
Sheiner, E., Har-Vardi, I. and Potashnik, G. (2001) The potential association
between blastocyst transfer and monozygotic twinning. Fertil. Steril., 75,
217±218.
Sinclair, K.D., Young, L.E., Wilmut, I. and McEvoy, T.G. (2000) In-utero
overgrowth in ruminants following embryo culture: lessons from mice and
a warning to men. Hum. Reprod., 15 (Suppl. 5), 68±86.
Smitz, J., Cortvrindt, R. and Hu, Y. (1998) Epidermal growth factor combined
with recombinant human chorionic gonadotrophin improves meiotic
progression in mouse follicle-enclosed oocyte culture. Hum. Reprod., 13,
664±669.
Sullivan, M.W., Stewart, E., Krasnow, J.S. et al. (1999) Ovarian response in
women to recombinant follicle stimulating hormone and luteinizing
hormone: a role for LH in the ®nal stages of follicular maturation. J. Clin.
Endocrinol. Metab., 84, 228±232.
Testart, J. (1988) Results of in-vitro fertilisation with embryo cryopreservation
and a recommendation for uniform reporting. Fertil. Steril., 49, 156±158.
Van Royen, E., Mangelschot, K., De Neubourg, D., Laureys, I., Ryckaert, G.
and Gerris, J. (2001) Calculating the implantation potential of day 3
embryos in women younger than 38 years of age: a new model. Hum.
Reprod., 16, 326±332.
Veeck, L., Amundsen, C., Brothman, L. et al. (1993) Signi®cantly enhanced
pregnancy rates through cryopreservation and thaw of pronuclear stage
oocytes. Fertil. Steril., 59, 1202±1207.
Veiga, A., Sandalinas, M., Benkhalifa, M. et al. (1997) Laser blastocyst biopsy
for preimplantation diagnosis in the human. Zygote, 5, 351±354.
Vendola, K., Zhou, J., Wang, J., Famuyiwa, O.A., Bievre, M. and Bondy, C.A.
(1999) Androgens promote insulin-like growth factor I expression and
initiation of follicle development in the primate ovary. Biol. Reprod., 61,
353±357.
Wennerholm, U., Hamberger, L. Nilsson, L. et al. (1997) Obstetric and
perinatal outcome of children conceived from cryopreserved embryos.
Hum. Reprod., 12, 1819±1825.
Wennerholm, U., Albertsom-Wikland, K., Bergh, C. et al. (1998) Postnatal
growth and health of children born after cryopreservation as embryos.
Lancet, 351, 1085±1090.
Westergaard, L.G., Laursen, S.B. and Yding Andersen, C. (2000) Increased
risk of early pregnancy loss by profound suppression of luteinizing
hormone during ovarian stimulation in normogonadotrophic women
undergoing assisted reproduction. Hum. Reprod., 15, 1003±1008.
Yan, C., Wang, P., DeMayo, J. et al. (2001) Synergistic roles of bone
morphogenetic protein 15 and growth differentiation factor 9 in ovarian
function. Mol. Endocrinol., 15, 854±866.
Young, C.E., Fernandez, K., McEvoy, T.G. et al. (2001) Epigenetic change in
IGF2R is associated with fetal overgrowth after sheep embryo culture.
Nature Genet., 27, 153±154.
Received on June 18, 2001; accepted on October 12 ,2001
9